199P - Prevalence of cervical cancer in Uzbekistan: A population based study

Background

Cervical cancer is the third most frequent disease among women in the world, which accounts for more than 9% of the total number of newly diagnosed malignant neoplasms in the female population, with more than 85% of newly diagnosed cervical cancer cases seen in developing countries. In the Republic of Uzbekistan, cervical cancer remains the most common cancer type and the leading cause of cancer death.

Methods

To analyze the cervical cancer burden we collected incidence data and TNM stage on cervical cancers from official statistics from Uzbekistan for years 2010-2019.

Results

In the structure of the general oncological morbidity over the last 10 years, cervical cancer takes 3rd place, but among the female population 2nd place. Analysis of the number of cervical cancer cases shows that over the 10-year period there were registered 14 499 (6.9%) new cervical cancer cases and 210 881 cases of all malignant neoplasms. Incidence rate tended to increase from 4.3in 2010 to 5.6 in 2019 per 100 thousand population. For the period 2010-2019 the age category of patients with cervical cancer was distributed as follows: patients under 15 years old were 1 (0.01%), at the age of 15-17 years - 4 (0.03%), from 18-44 years - 3777 (26 , 1%), 45-64 years old - 8963 (61.8%), 65 years and older - 1754 (12.1%). In 2010 and 2019, over 41% and 28% cervical cancers in Uzbekistan were registered at stages III-IV, but 57.8% and 67.0% cervical cancers were registered at stages I-II accordingly. Moreover 7 662 patients died from cervical cancer over the last 10 years, while the mortality rate was 2.3 in 2010, and 3.0 in 2019 per 100 thousand population.

Conclusions

In conclusion it can be shown that cervical cancer morbidity has the tendency to increase in the Republic of Uzbekistan. 45-65-year-old women are more likely to develop cervical cancer in the Republic. Over the last 10 years, there has been a decrease of advanced (III-IV) stages of cervical cancer cases. The increase in morbidity is due to implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.